Compare HON & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HON | SNY |
|---|---|---|
| Founded | 1885 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.8B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | HON | SNY |
|---|---|---|
| Price | $196.31 | $48.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $238.92 | $61.50 |
| AVG Volume (30 Days) | ★ 3.8M | 2.6M |
| Earning Date | 02-05-2026 | 01-29-2026 |
| Dividend Yield | 2.44% | ★ 3.31% |
| EPS Growth | 9.45 | ★ 105.93 |
| EPS | ★ 9.47 | 8.67 |
| Revenue | $40,670,000,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $7.05 | $1.73 |
| Revenue Next Year | N/A | $6.49 |
| P/E Ratio | $20.64 | ★ $5.57 |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $179.36 | $44.62 |
| 52 Week High | $241.72 | $60.12 |
| Indicator | HON | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 45.38 |
| Support Level | $194.72 | $47.70 |
| Resistance Level | $202.46 | $48.74 |
| Average True Range (ATR) | 2.88 | 0.64 |
| MACD | 0.71 | 0.01 |
| Stochastic Oscillator | 56.07 | 50.36 |
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.